When targeting glucose metabolism, rapamycin, which inhibits glycolysis through suppressing the mTOR pathway, also shows synergistic antitumor activity with salubrinal in cholangiocarcinoma cells [54]. The gene discussed is MTOR; the disease is cholangiocarcinoma.